ArticleJournal of comparative effectiveness research2023
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant.
Ernest H Law et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.